Moderna announced plans Thursday to increase the global supply of the company's COVID-19 vaccine to 3 billion doses next year.The Cambridge, Massachusetts, company said new funding investments will allow them to increase their forecast to 1 billion doses this year and 3 billion in 2022. That includes potential boosters and doses for children. Moderna raised its 2021 manufacturing supply forecast to between 800 million to 1 billion doses. “As we follow the rapid spread of SARS-CoV-2 variants of concern, we believe that there will continue to be significant need for our mRNA COVID-19 vaccine and our variant booster candidates into 2022 and 2023. We are hearing from governments that there is no technology that provides the high efficacy of mRNA vaccines and the speed necessary to adapt to variants, while allowing reliable scalability of manufacturing,” said Stephane Bancel, chief executive officer of Moderna. Moderna also announced that ongoing development data related to the current formulation of the the vaccine could support a 3-month refrigerated shelf life for the vaccine in alternative formats to facilitate easier distribution to doctor’s offices and other smaller settings if authorized. Currently, the Moderna COVID-19 vaccine is approved for storage up to 1 month at refrigerated temperatures and up to 7 months in a standard freezer. 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
CAMBRIDGE, Mass. — Moderna announced plans Thursday to increase the global supply of the company's COVID-19 vaccine to 3 billion doses next year.
The Cambridge, Massachusetts, company said new funding investments will allow them to increase their forecast to 1 billion doses this year and 3 billion in 2022. That includes potential boosters and doses for children.
Moderna raised its 2021 manufacturing supply forecast to between 800 million to 1 billion doses.
“As we follow the rapid spread of SARS-CoV-2 variants of concern, we believe that there will continue to be significant need for our mRNA COVID-19 vaccine and our variant booster candidates into 2022 and 2023. We are hearing from governments that there is no technology that provides the high efficacy of mRNA vaccines and the speed necessary to adapt to variants, while allowing reliable scalability of manufacturing,” said Stephane Bancel, chief executive officer of Moderna.
Moderna also announced that ongoing development data related to the current formulation of the the vaccine could support a 3-month refrigerated shelf life for the vaccine in alternative formats to facilitate easier distribution to doctor’s offices and other smaller settings if authorized.
Currently, the Moderna COVID-19 vaccine is approved for storage up to 1 month at refrigerated temperatures and up to 7 months in a standard freezer.
